Introduction
The pharmacy benefit management (PBM) industry has come under increasing scrutiny from regulators and policymakers due to its growing market concentration. A new study published in the Journal of the American Medical Association (JAMA) sheds light on why the largest PBMs—CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum Rx—are focusing on specific payer segments. These targeted strategies may help PBMs maintain their market share, but they also raise concerns about accessibility and costs for patients.
What is Pharmacy Benefit Management (PBM)?
Pharmacy Benefit Managers (PBMs) play a crucial role in the healthcare system by managing prescription drug benefits on behalf of insurers, Medicare Part D drug plans, large employers, and other payers. PBMs negotiate prices with drug manufacturers, determine which drugs will be covered by insurance plans, and manage pharmacy networks where patients fill prescriptions.
Market Share of the Largest PBMs
The recent analysis highlights significant trends in how the largest PBMs control various segments of the market.
CVS Health’s Caremark Dominance in Medicaid
According to the study, CVS Health’s Caremark has the largest overall market share in the PBM sector, controlling a substantial 31.3% of the market. However, its most significant hold is in Medicaid managed care, where it controls 39.2% of the market. This margin puts CVS well ahead of its competitors, as Cigna’s Express Scripts controls 12.3%, and Optum Rx holds 15.8% in Medicaid.
This dominance raises concerns about market concentration, especially since Medicaid beneficiaries may have CVS pharmacies designated as their preferred providers. As Dr. Dima Qato, Ph.D., of the University of Southern California pointed out, this could limit access for Medicaid patients who may have other pharmacies closer to them but are forced to visit CVS due to their PBM’s preferences.
Express Scripts’ Stronghold in the Commercial Market
Express Scripts, a part of Cigna, holds a strong position in the commercial insurance market, where it controls 28% of the market share, nearly matching CVS at 28.5%. Optum Rx lags behind, controlling just 16.4%. Express Scripts’ prominence in this space is notable because commercial plans often serve working-age populations, and the PBM’s ability to manage costs effectively can significantly impact employers and employees.
Optum Rx’s Presence in Medicare Part D
Optum Rx, part of UnitedHealth Group, has the most substantial share of its business in the Medicare Part D space. The study found that Optum controls 27.7% of the Medicare market, trailing only CVS Health, which holds 33.4%. Express Scripts, by comparison, controls 15.4% of Medicare Part D.
Concerns Raised by Market Concentration
Impact on Medicaid Beneficiaries
The concentration of the Pharmacy Benefit Managers market, particularly in Medicaid, raises significant concerns about access to pharmacies. Dr. Qato highlighted that patients might unknowingly visit a non-preferred pharmacy, which could result in increased out-of-pocket costs. This situation could lead to decreased medication adherence, as patients may struggle to afford their medications or access their nearest pharmacy.
Effect on Medication Adherence
The report suggests that PBMs, especially those with a dominant market share like CVS, may inadvertently increase costs for patients by restricting access to preferred pharmacies. Patients who cannot easily reach a CVS pharmacy may face higher prices at non-preferred locations, which could lead to non-adherence to prescribed medications. This lack of adherence can exacerbate health conditions and lead to higher overall healthcare costs in the long term.
Study Methodology
The study utilized data from IQVIA’s National Prescription Audit PayerTrak, analyzing 14 billion prescriptions across 91 PBMs in 2023. The research also employed the Herfindahl-Hirschman Index (HHI) to assess market concentration. The HHI is a commonly used measure of market competition, with higher scores indicating greater concentration.
Policymaker and Regulatory Concerns
The JAMA study is the second report within a week to analyze the concentration in the PBM sector, which has been a long-standing concern among policymakers. The American Medical Association reported that the top four PBMs, including CVS, Express Scripts, Optum, and Prime Therapeutics, control over 70% of the market.
In July, the Federal Trade Commission (FTC) issued a report highlighting concerns over the vertical integration of PBMs with insurers. The FTC report emphasized that such consolidation warrants further scrutiny and could lead to increased regulation to ensure fair market practices and protect consumers.
Future Implications of Pharmacy Benefit Managers Market Trends
The concentration of power among the largest PBMs could lead to significant changes in how prescription drug benefits are managed. If these trends continue, smaller PBMs may struggle to compete, leading to even less competition in the market. This could result in fewer options for patients and payers alike, and increased scrutiny from regulators may prompt changes in how Pharmacy Benefit Managers are allowed to operate.
The future of the PBM industry will likely involve more transparency and accountability, especially as policymakers continue to analyze how market concentration affects patient access to medications and healthcare disparities.
Conclusion
The concentration of market share among the largest Pharmacy Benefit Managers, such as CVS Health, Express Scripts, and Optum Rx, has significant implications for patients, especially those on Medicaid and Medicare. While these companies have succeeded in controlling key payer segments, concerns over access to preferred pharmacies, cost management, and medication adherence continue to grow. As policymakers and regulators focus on PBM market practices, increased oversight and regulation may be necessary to ensure that patients can access affordable and convenient pharmacy services.
Discover the latest payers’ news updates with a single click. Follow DistilINFO HealthPlan and stay ahead with updates. Join our community today!
FAQs
Q1: What is a Pharmacy Benefit Manager?
A1: A PBM is an intermediary that manages prescription drug benefits for health plans, negotiating prices with drug manufacturers and creating pharmacy networks.
Q2: Why are policymakers concerned about Pharmacy Benefit Managers?
A2: Policymakers are concerned about market concentration among PBMs, which can limit access to pharmacies and increase costs for patients.
Q3: Which Pharmacy Benefit Managers has the largest market share in Medicaid?
A3: CVS Health’s Caremark holds the largest market share in Medicaid, controlling 39.2% of the market.
Q4: What role does the Herfindahl-Hirschman Index (HHI) play in Pharmacy Benefit Managers analysis?
A4: The HHI measures market concentration, with higher scores indicating less competition, which is a concern in the Pharmacy Benefit Managers industry.